Pharmaceutical Technology's Equipment and Machinery Spending Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Equipment and Machinery Spending Survey
The pharmaceutical industry plans moderate increases in spending for equipment and machinery in 2007 as expenditures hold steady.

Pharmaceutical Technology



Figure 3
The increase in the percentage of respondents indicating spending of 2.1–4% of their overall company's revenues seems to have come at the expense of higher levels of spending.Three ranges of spending declined in 2007 over 2006. Only 6.4% of respondents say their companies plan to spend 6.1–8% of their overall revenues on equipment and machinery in 2007, compared with 12.2% in 2006. Only 4.2% plan to spend 8.1–10% of their overall revenues on machinery and equipment in 2007, compared with 6.2% in 2006. And, only 4.3% plan to spend greater than 10% of their overall revenues on equipment and machinery in 2007, compared to 12.2% in 2006.

In terms of absolute dollar amounts, almost three-fourths of the respondents (72.3%) say their companies plan to spend $10 million or less on equipment and machinery in 2007 (see Figure 3). In 2006, 60.4% of the respondents said their companies increased spending by $10 million or less, and 18.8% increased spending by $11–50 million (see Figure 3).


Figure 4
For 2007, spending at moderate levels is increasing over 2006. In 2007, 12.5% of the respondents plan to increase spending 4.1-6%; only 6.3% increased spending by this level in 2006. In 2007, 29.2% of the respondents plan to increase spending by 2.1-4%; in 2006, only 18.7% increased spending by this level. (see Figure 4).



Spending trends


Figure 5
In analyzing spending trends, 46.8% of respondents said that their company's growth in spending on machinery and equipment is holding steady, and 8.5% of respondents said their spending will grow faster in 2007 than in 2006 (see Figure 5). Over the past two years (2006 and 2005), 40.8% said that spending growth held steady, and 20.4% said that it grew faster year over year. Consistent with 2005 and 2006 spending levels, 10.6% of respondents say spending on equipment and machinery is contracting in 2007 (spending less in 2007 than in 2006), and 21.3% of respondents say their spending growth is slowing (rate of increase is less year-over-year).

Reasons for increasing spending


Figure 6
Facilities expansion and new or expanded projects were the major reasons behind growth in spending in 2006 and planned spending for 2007 (see Figure 6). In 2006, 71.4% of respondents increased spending on machinery and equipment because of facilities expansion or new or expanded projects, and 78.1% responded similarly for spending planned in 2007. Roughly one-quarter (21.9% in 2007 and 25.7% in 2006) of the respondents said spending growth resulted from the replacement of existing equipment.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here